Europe Will Expand Access to Psychedelic-Assisted Therapy with New Norway Clinic – Awaken Life Sciences (OTC:AWKNF)

psychedelic Biotechnology Awak Life Sciences Corporation AWKNF announced Continuation of its Nordic expansion plans With new 5 year lease to open clinic in the center of Trondheim.

Awake’s CEO Anthony Tennyson said it was “growing real momentum” for the company in Norway.

“To be able to share news in the space of a week Our move to a new larger campus in Oslo And a completely new clinic in Trondheim is very exciting. For so many people who are suffering and are in desperate need of a new and more effective treatment, this will be great news,” Tennyson said.

The company’s Nordic expansion is led by its Regional Director for Nordics, Dr. Lovan Stewart, who is a well-known figure in the medical community and is responsible for the adoption of ketamine therapy in Norway’s public health system.

The new Trondheim facility will be led by prominent Norwegian psychiatrist Dr. Ingrid Kasterberg, and will include a 3-treatment room clinic totaling 1,400 square feet, expected to be ready sometime in March or April 2023.

Awakn’s core ketamine treatment protocols are implemented in the company’s clinics with each client’s mental health status in mind. Speechless CMO Ben Sessa told Benzinga earlier this year,

In particular, the Alcohol Use Disorder (AUD) protocol has provided strong positive results with the company partnering with Many Ketamine Centers in North America For licensing agreements for the implementation of this therapy in businesses owned by Awakn.

Photo by Micheljung via Shutterstock and Wikimedia Commons.

Source link

Leave a Comment